[Sonnet BioTherapeutics Shareholders Approve Proposed Business Combination with Hyperliquid Strategies Inc] Odaily Planet Daily reports that according to a press release issued by Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), Sonnet announced that its shareholders approved the proposed business combination with Hyperliquid Strategies Inc (HSI) and Rorschach I LLC during a special meeting. The final voting results will be submitted to the U.S. Securities and Exchange Commission (SEC) via a Form 8-K filing. Sonnet is a biotechnology company focused on oncology, with a proprietary biologics innovation platform called FHAB (Fully Human Albumin Binding). This technology utilizes human serum albumin (HSA) to deliver drugs to target tissues, aiming to enhance the safety and efficacy of immunomodulatory biologics. Under the proposed business combination transaction, the Form S-4 registration statement filed by HSI became effective on October 27, which includes a proxy statement for use by Sonnet shareholders and will also serve as HSI's prospectus. Upon completion of the proposed business combination, HSI's securities are expected to be listed on Nasdaq.